Tempest Therapeutics (TPST) Stock Price, News & Analysis

Company Overview

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells. Additional preclinical programs aim to block key kinases involved in immune suppression, thereby complementing existing checkpoint inhibitors. Tempest has initiated early‐phase clinical studies in North America and Europe, collaborating with academic and industry partners to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with advanced malignancies.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Tempest Therapeutics was established to translate cutting‐edge metabolic and immunological insights into novel oncology treatments. The company’s leadership team combines expertise in drug discovery, clinical development, and regulatory strategy, with decades of experience at both emerging biotechnology firms and large pharmaceutical companies. Tempest is supported by leading life‐science investors and maintains research collaborations to expand its pipeline and accelerate the delivery of new therapies to patients worldwide.

Key Stats

• Today's Range: $10.40 to $11.14
• 50-Day Range: $6.25 to $11.00
• 52-Week Range: $5.33 to $20.67
• Volume: 70,091 shs
• Average Volume: 91,555 shs
• Market Capitalization: $47.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Moderate Buy

Tempest Therapeutics Stock Analysis - MarketRank™

Tempest Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 699th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tempest Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Tempest Therapeutics has a consensus price target of $30.00, representing about 184.0% upside from its current price of $10.57.

Amount of Analyst Coverage

Tempest Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tempest Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.39% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently decreased by 14.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempest Therapeutics does not currently pay a dividend.

Dividend Growth

Tempest Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.39% of the float of Tempest Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tempest Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempest Therapeutics has recently decreased by 14.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

8 people have searched for TPST on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

3 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of Tempest Therapeutics is held by insiders.

Percentage Held by Institutions

Only 22.52% of the stock of Tempest Therapeutics is held by institutions.

TPST Stock Analysis - Frequently Asked Questions

How have TPST shares performed this year?

Tempest Therapeutics' stock was trading at $10.8485 on January 1st, 2025. Since then, TPST stock has decreased by 2.6% and is now trading at $10.5650.

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings data on Monday, August, 11th. The company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.23) by $1.16.

When did Tempest Therapeutics' stock split?

Tempest Therapeutics shares reverse split on the morning of Friday, June 25th 2021.The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Tempest Therapeutics' major shareholders?

Tempest Therapeutics' top institutional shareholders include Versant Venture Management LLC (7.33%), Geode Capital Management LLC (0.94%), Group One Trading LLC and Belvedere Trading LLC. Insiders that own company stock include Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski and Samuel Whiting.
View institutional ownership trends.

How do I buy shares of Tempest Therapeutics?

Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tempest Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tempest Therapeutics investors own include Meta Platforms (META), Cloudflare (NET), NVIDIA (NVDA), Snowflake (SNOW), Tesla (TSLA), Intel (INTC) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TPST
• CIK: 1544227
• Web: www.millendo.com
• Phone: 415-798-8589
• Fax: N/A
• Employees: 20
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Tempest Therapeutics: $30.00
• High Price Target: $65.00
• Low Price Target: $9.00
• Potential Upside/Downside: +172.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -334.76%
• Return on Assets: -130.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.12
• Quick Ratio: 2.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.66 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 4,440,000
• Free Float: 4,231,000
• Market Cap: $48.84 million
• Optionable: Optionable
• Beta: -1.93